NBIX — Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: Exceeded $800 million for the first time, marking a 44% year-over-year growth.
• INGREZZA Sales: $657 million, up 20% year-over-year, driven by new patient additions. Adjusted growth, accounting for one less order week in Q1 2025, was approximately 11%.
• Cranesity Sales: $153 million, benefiting from strong persistency and new patient enrollment.
• Net Income: Approximately $200 million on both GAAP and non-GAAP bases, reflecting strong operational execution.
• Guidance for INGREZZA: Reaffirmed at $2.7 to $2.8 billion for 2026.

2. Strategic Updates and Business Highlights

• Acquisition of Soleno Therapeutics: Expected to close in Q2 2026, aiming to enhance the company's portfolio, particularly for Prader-Willi syndrome.
• Pipeline Development: Plans for six new phase 1 and four new phase 2 programs in 2026, with key data readouts anticipated in 2027 for multiple candidates.
• Commercial Expansion: Continued investment in sales force and marketing initiatives, particularly for INGREZZA and Cranesity, to drive growth and improve patient access.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated strong performance across commercial products and pipeline advancements. The company is optimistic about sustaining growth momentum through the year.
• Sales Force Impact: The expanded sales team is expected to enhance patient acquisition and retention, particularly for Cranesity.

4. Bad News, Challenges, or Points of Concern

• Gross-to-Net Pressure: Slight pressure observed in Q1 due to commercial copay resets.
• Market Dynamics: Potential competitive pressures from changes in payer coverage for INGREZZA, particularly concerning the loss of preferred coverage for deuterated tetrabenazine in some plans.
• Seasonality Effects: Historical seasonality in Q1 impacting sales, though the company managed it effectively this year.

5. Notable Q&A Insights

• Cranesity Growth: The launch is ahead of expectations, with steady new patient starts and high persistency rates. However, the majority of physicians have only treated one patient, indicating significant growth potential.
• Pipeline Clarity: Phase 3 programs for major depressive disorder and schizophrenia are enrolling well, with readouts expected next year.
• Market Penetration: Approximately 90% of TD patients are not receiving standard treatment, highlighting a substantial opportunity for INGREZZA.
• Reauthorization Trends: High rates of reauthorization approvals for Cranesity, with no significant issues reported regarding insurance-related discontinuations.

Overall, Neurocrine Biosciences demonstrated strong financial performance in Q1 2026, with a positive outlook driven by strategic initiatives and a robust pipeline, despite facing some competitive and market challenges.